USA flag logo/image

An Official Website of the United States Government

Amniotic Membrane versus Pericardium in Reducing Glaucoma Drainage Tube Exposure

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R44EY019785
Solicitation Year:
2012
Solicitation Topic Code:
NEI
Solicitation Number:
PA10-050
Small Business Information
TISSUETECH, INC.
7000 SW 97 AVENUE SUITE 212 MIAMI, FL -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: Amniotic Membrane versus Pericardium in Reducing Glaucoma Drainage Tube Exposure
Agency: HHS
Contract: 2R44EY019785-02
Award Amount: $997,132.00
 

Abstract:

DESCRIPTION (provided by applicant): Glaucoma drainage devices (GDDs) have widely been used in the treatment of high-risk refractory glaucoma. To avoid tube exposure, which may lead to serious eye infection, the implanted GDD tube must be covered by apatch graft traditionally made of either donor sclera or pericardium. However, these patch grafts still carry a high rate of progressive thinning and erosion, a complication that we speculate results from the lack of cellular infiltration from the surrounding host conjunctival stroma and poor integration of these patch grafts to the host tissue. We further speculate that a thicker version of cryopreserved amniotic membrane (AM), manufactured by Bio-Tissue, Inc., a 100%-owned subsidiary of TissueTech, Inc.,could offer better tensile strength, be suitable for tectonic support, and have biological activities to promote cellular infiltration by the surrounding host conjunctival stroma, thus reducing progressive allogeneic patch graft thinning/erosion. ThroughSBIR Phase I grant support (R43 EY19785), we have evaluated the thicker AM as an alternative patch graft for covering the GDD tube during the primary implantation. We further monitored the host cell interaction using anterior segment optical coherence tomography (OCT). We have successfully accomplished the proposed aims of the above studies which demonstrated the short-term stability/efficacy of AM in covering the tube in primary GDD surgery (Phase I- Aim 1), and confirmed the feasibility of using OCT to distinguish host cell infiltration into the AM after transplantation over the GDD tube (Phase I- Aim 2). In this Phase II application, we propose to conduct a prospective, controlled study to compare the long-term safety and efficacy of the thicker AM (AmnioGuard , Bio-Tissue, Inc, Miami, FL) to the pericardium (Tutoplast(R), IOP Inc, Costa Mesa, CA) in securing the GDD tube and reducing tube exposure and graft thinning in patients with high risk glaucoma. We will also study the risk factors that may contribute to GDD tube exposure. Accomplishment of this Phase II study will position AM as an effective alternative to the existing patch grafts to reduce tube exposure and enhance the success of GDD implantation while providing a better aesthetic appearance andallowing visualization of the tube in patients with high risk glaucoma. This will also allow the Company to expand its market space from ocular surface to glaucoma diseases. We speculate that such a graft might also have other clinical applications outside of covering GDD tubes. PUBLIC HEALTH RELEVANCE: Our proposed prospective, randomized and comparative study described in this Phase II application aims to demonstrate the clinical safety and efficacy of transplanting a thicker version of amniotic membrane (AM) as an alternative tectonic substrate to cover glaucoma drainage device (GDD) tubes. Through SBIR Phase I grant support (EY019785), we found that this thicker AM offers superior tectonic support and biological activity to promote integration by the host conjunctival stromal cells, thus reducing patch graft thinning/erosion. The completion of the study described herein will allow eye surgeons to adopt this new AM graft to improve surgical outcomes and prevent complications in GDD surgery forhigh risk glaucoma patients. This will also allow the Company to expand its market space and provide services to glaucoma indications.

Principal Investigator:

Hosam El sheha
305-412-4431
hsheha@biotissue.com

Business Contact:

Nelson A. Vega
305-412-0098
nvega@tissuetechinc.com
Small Business Information at Submission:

TISSUETECH, INC.
7000 SW 97 AVENUE SUITE 212 MIAMI, FL -

EIN/Tax ID: 165111607
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No